Premium
Pityriasis rubra pilaris exacerbation with topical use of imiquimod
Author(s) -
Yang F. Clarissa,
Jessup Chad,
Dahiya Madhu,
Reynolds Rachel
Publication year - 2008
Publication title -
international journal of dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.677
H-Index - 93
eISSN - 1365-4632
pISSN - 0011-9059
DOI - 10.1111/j.1365-4632.2008.03729.x
Subject(s) - pityriasis rubra pilaris , imiquimod , medicine , dermatology , exacerbation , actinic keratosis , tlr7 , pityriasis rosea , immune system , immunology , psoriasis , toll like receptor , pathology , innate immune system , basal cell
The role of immune response modifiers is increasing in the treatment of dermatologic diseases. Imiquimod, a toll‐like receptor agonist, results in up‐regulation of proinflammatory cytokines for improved immune surveillance. Although topical use is generally well‐tolerated, imiquimod can potentially result in systemic effects and exacerbate generalized inflammatory papulosquamous diseases of the skin. We report the case of a 67‐year‐old man who was treated with imiquimod for actinic keratosis and developed fever and a progressive erythematous papulosquamous eruption that was histologically consistent with pityriasis rubra pilaris.